DrugInformations.org

United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of an inhaled formulation of treprostinil (ITRE) for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disease. The submission starts a 60-day period during which the FDA will examine the application for completeness.

More: continued here

No Comments »

Men are one-quarter less likely than women to know that they have high blood pressure and black men with high blood pressure, are particularly unlikely to know of their condition, according to study published in the Archives of Internal Medicine, Reuters Health reports. For the study, lead researcher Ronald Victor of the University of Texas’

More: continued here

No Comments »

AstraZeneca announced a European decentralized procedure (DCP) submission seeking approval for two new dose strengths of Atacand Plus, for those hypertensive patients not optimally controlled by monotherapy. The reference member state for the procedure is Sweden, and the submission incorporates data from three studies. 1,2,3 The new strengths of the fixed dose combination Atacand Plus, comprised of candesartan cilexetil and hydrochlorothiazide (HCT) in doses of 32/12.

More: continued here

No Comments »

Results of a new analysis of the Treating to New Targets (TNT) study show that intensive low-density lipoprotein (LDL) cholesterol-lowering in patients with stable coronary heart disease (CHD) whose systolic blood pressure was less than 140 mmHg reduced the risk of major cardiovascular events, including heart attack, stroke and resuscitated cardiac arrest, by 42 percent compared with less intensive LDL lowering and uncontrolled blood pressure of 140 mmHg or higher. Led by John B.

More: continued here

No Comments »

Working hard when fatigued may be admired by many Americans, but it is a virtue that could be harmful to one’s health, according to new research by psychologists at the University of Alabama at Birmingham (UAB). The research supports a theory which suggests that exhausted individuals’ cardiovascular systems are forced to work harder when they attempt to complete tasks, such as those encountered on the job or at school.

More: continued here

No Comments »

Healthy individuals with higher levels of albumin excretion, even levels considered normal, are at increased risk of developing hypertension (high blood pressure), according to a study appearing in the October 2008 issue of the Journal of the American Society Nephrology (JASN). The study suggests that to prevent cardiovascular disease, the definition of “normal” urinary albumin excretion should be reconsidered.

More: continued here

No Comments »

Insomniacs who sleep fewer than five hours a night are five times more likely to suffer hypertension than people who sleep well, according to a major study that highlights the growing concerns over links between sleep problems and serious illness.

More: continued here

No Comments »

A new study suggests that American men are much more likely than women are to be unaware that they suffer from high blood pressure. African-American men with the condition are at the highest risk, with only one in seven both aware of their illness and able to control it through medication.

More: continued here

No Comments »

A research project at the University of Leicester in conjunction with the University of East Anglia, indicates that early reduction of high blood pressure following stroke is feasible and safe, and both Labetalol & Lisinopril were found to be suitable a medications for this purpose. Larger studies will now be necessary to confirm this result and test the effects on recovery from stroke.

More: continued here

No Comments »

The Medicines Company (NASDAQ: MDCO) today announced that data from two post-hoc analyses of the ECLIPSE trial showed that use of Cleviprex? (clevidipine butyrate) injectable emulsion to control blood pressure during cardiac surgery may be associated with a reduced risk of heart attack compared to two of three currently used IV antihypertensive agents. In a separate sub-analysis, Cleviprex was associated with a lower 30-day mortality compared to two nitrovasodilators.

More: continued here

No Comments »